← Back to home

Castration-resistant prostate carcinoma refractory to second-generation androgen receptor axis-targeted agents

Clinical trials for Castration-resistant prostate carcinoma refractory to second-generation androgen receptor axis-targeted agents explained in plain language.

Never miss a new study

Get alerted when new Castration-resistant prostate carcinoma refractory to second-generation androgen receptor axis-targeted agents trials appear

Sign up with your email to follow new studies for Castration-resistant prostate carcinoma refractory to second-generation androgen receptor axis-targeted agents, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Terminated 1

Experimental drug shows promise for Hard-to-Treat prostate cancer

Disease control Stopped early

This phase 2 study tested the drug erdafitinib in 11 men with castration-resistant prostate cancer that had spread to the bone. The goal was to see if the drug could slow the cancer and to study bone and blood markers. The trial was terminated early, so results are limited.

Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA REFRACTORY TO SECOND-GENERATION ANDROGEN RECEPTOR AXIS-TARGETED AGENTS

Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control

Last updated Jun 27, 2026 09:02 UTC

Castration-resistant prostate carcinoma refractory to second-generation androgen receptor axis-targeted agents

Get alerted when new Castration-resistant prostate carcinoma refractory to second-generation androgen receptor axis-targeted agents trials appear

Experimental drug shows promise for Hard-to-Treat prostate cancer